A deep dive into Eli Lilly’s tantalizing data on Alzheimer’s disease

What is that?

STAT + is STAT’s premium subscription service for in-depth coverage and analysis in biotechnology, pharmacy, policy and life sciences. Our award-winning team covers the news on Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, and the disruption of healthcare in Silicon Valley and beyond.

What is included?

• Daily reports and analyzes
• The most comprehensive coverage in the industry by a team of powerful journalists
• Subscriber newsletters
• Daily newsletters to keep you informed about the most important news in the sector
• STAT + conversations
• Weekly opportunities to engage with our journalists and leading industry experts in live video chats
• Exclusive industry events
• Premium access to subscriber-only networking events nationwide
• The best reporters in the industry
• The most reliable and most connected newsroom in the healthcare industry
• And much more
• Exclusive interviews with industry leaders, profiles and high-end tools, like our CRISPR Trackr.